Every four years, many of us settle in for hours of Olympic figure skating—team events, ice dance, pairs, women’s, and men’s.
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results